预约演示

更新于：2025-03-20

Dextran/D-Glucopyranose

更新于：2025-03-20

概要

概要

基本信息

药物类型

小分子化药

别名

Dextran 40/Glucose、LOW MOLECULAR DEXTRAN D INJECTION、低分子デキストラン糖注

靶点-

作用方式-

作用机制-

治疗领域

心血管疾病其他疾病

在研适应症

休克血栓形成

非在研适应症-

原研机构

Otsuka Pharmaceutical Factory, Inc.

在研机构

Otsuka Pharmaceutical Factory, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1970-05-19),

休克血栓形成

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C6H12O6

InChIKeyWQZGKKKJIJFFOK-GASJEMHNSA-N

CAS号2280-44-6

关联

项与 Dextran/D-Glucopyranose 相关的临床试验

ACTRN12609000673246

/ Recruiting临床2期IIT

A Multicentre, Randomised, Placebo contolled trial of intravenous 10% Dextran 40 (Rheomacrodex), in the Prevention of Stroke in Carotid Surgery

开始日期2002-01-01

申办/合作机构-

100 项与 Dextran/D-Glucopyranose 相关的临床结果

登录后查看更多信息

100 项与 Dextran/D-Glucopyranose 相关的转化医学

登录后查看更多信息

100 项与 Dextran/D-Glucopyranose 相关的专利（医药）

登录后查看更多信息

项与 Dextran/D-Glucopyranose 相关的文献（医药）

2008-12-15·Zhonghua wai ke za zhi [Chinese journal of surgery]

[The early diagnosis and treatment of fat embolism syndrome caused by the injuries in Wenchuan earthquake].

Article

作者: Kang, Bin ; Wang, Tao ; Wang, Jun ; Xiang, Jia ; Yang, Heng

OBJECTIVETo analysis and discuss the early diagnosis and treatment of fat embolism syndrome caused by the injuries in Wenchuan earthquake happened in May 12th, 2008.METHODSTo carry out dynamic blood and oxygen analysis and blood routine examination for the 13 fat embolism syndrome patients wounded in the earthquake, and combine with clinical features and early diagnosis, inject hydrocortisone injection, dextran 40 glucose injection and Dan Shen Root injection. Meanwhile, pay attention to supporting the respiratory function and correcting hypoxemia.RESULTSOf 13 patients, 12 cases were rescued successfully, and the successful rate was 92.3%, while one cases died from respirometric failure with fat embolism syndrome and secondary hemorrhagic pneumonia.CONCLUSIONSThe key to treating fat embolism syndrome is the early diagnosis and timely and accurate treatment. Supporting the respiratory function, correcting hypoxemia and early high-dose combination of hormone treatment are the effective treatment methods.

2002-03-01·Se pu = Chinese journal of chromatography

Endotoxin removal in some medicines and human serum albumin solution by affinity membranes.

Article

作者: Liu, Xue-Liang ; Li, Jing-Hua ; Wei, Gui-Lin ; Shang, Zhen-Hua ; Liu, Ying

Three kinds of affinity membranes utilized for endotoxin removal, namely, chitosan affinity membrane (KFCC517), hydrophobic and cationic charged membrane (KFCG316) and metal chelate affinity membrane (KFCM402) were prepared by using cellulose membrane as support. The adsorbability and applications of the membranes in endotoxin removal were investigated. The results showed that all of these affinity membranes could be utilized for endotoxin removal in several kinds of solutions. The factors affecting endotoxin removal such as ionic strength, pH value and flow rate were investigated, and the results were discussed. Three cartridges of membranes KFCC517, KFCG316 and KFCM402 were utilized for endotoxin removal in human serum albumin solution. The cartridge of membrane KFCC517 also was utilized in medicine injections, such as hydrocortisone, puerarin, tetracaine hydrochloride and dextran 40 glucose. Under the optimal conditions, the removal efficiencies of endotoxin were over 80% and the recoveries of desirable substances were over 95%.

100 项与 Dextran/D-Glucopyranose 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
休克	日本	Otsuka Pharmaceutical Factory, Inc.	1970-05-19
血栓形成	日本	Otsuka Pharmaceutical Factory, Inc.	1970-05-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2023	N/A	-	-	Low molecular weight iron dextran (LMW ID)	(鬱積壓糧鏇糧齋鏇鏇蓋) = 築鹽鹹選鹽選觸構構淵觸鹹遞願窪鬱壓鏇繭醖 (艱網艱醖鹹衊簾願構鏇 ) 更多	-	2023-12-10
				Low Molecular Weight Iron Dextran (Premedication)	(鬱積壓糧鏇糧齋鏇鏇蓋) = 願鏇糧餘夢餘鏇獵衊築觸鹹遞願窪鬱壓鏇繭醖 (艱網艱醖鹹衊簾願構鏇 )